T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan Chase
JPM
|
+$1.6B |
| 2 |
Verizon
VZ
|
+$1.3B |
| 3 |
US Bancorp
USB
|
+$1.26B |
| 4 |
Berkshire Hathaway Class B
BRK.B
|
+$1.26B |
| 5 |
Lam Research
LRCX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$6.33B |
| 2 |
Tesla
TSLA
|
+$5.64B |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$4.91B |
| 4 |
TMX
Terminix Global Holdings, Inc.
TMX
|
+$3.44B |
| 5 |
Meta Platforms (Facebook)
META
|
+$1.4B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.7% |
| 2 | Healthcare | 19.64% |
| 3 | Financials | 12.71% |
| 4 | Consumer Discretionary | 10.95% |
| 5 | Communication Services | 7.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CERE
426
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $152M | 0.02% |
4,804,594
+35,520
| +0.7% | +$1M |
|
427
PNC Financial Services
PNC
$102B
| $151M | 0.02% |
957,061
-262,823
| -22% | -$41.4M |
|
428
Howmet Aerospace
HWM
$113B
| $151M | 0.02% |
3,834,960
+395,751
| +12% | +$14.4M |
|
429
Lockheed Martin
LMT
$138B
| $149M | 0.02% |
307,235
-2,693
| -0.9% | -$1.25M |
|
|
RNAM
430
DELISTED
Avidity Biosciences
RNAM
| $149M | 0.02% |
6,707,287
+1,538,264
| +30% | +$22.9M |
|
431
Camden Property Trust
CPT
$11.1B
| $146M | 0.02% |
1,304,697
-143,285
| -10% | -$16.4M |
|
432
OneMain Financial
OMF
$7.51B
| $144M | 0.02% |
4,317,008
+1,204,312
| +39% | +$42.7M |
|
433
Magnolia Oil & Gas
MGY
$6.13B
| $144M | 0.02% |
6,127,937
+97,635
| +2% | +$2.38M |
|
434
Jackson Financial
JXN
$9.1B
| $143M | 0.02% |
4,104,473
+6,052
| +0.1% | +$210K |
|
|
APLS
435
DELISTED
Apellis Pharmaceuticals
APLS
| $142M | 0.02% |
2,749,542
-601,421
| -18% | -$31.9M |
|
436
Dollar Tree
DLTR
$24.9B
| $140M | 0.02% |
987,402
+44,157
| +5% | +$6.57M |
|
437
Sanofi
SNY
$105B
| $139M | 0.02% |
2,876,806
-9,420,070
| -77% | -$413M |
|
438
Zoom
ZM
$32.2B
| $139M | 0.02% |
2,050,503
-566,996
| -22% | -$43.1M |
|
439
NVR
NVR
$17B
| $139M | 0.02% |
30,042
-385
| -1% | -$1.69M |
|
|
EXE
440
Expand Energy Corp
EXE
$21.9B
| $138M | 0.02% |
1,462,502
+1,419,143
| +3,273% | +$141M |
|
441
Replimune Group
REPL
$1.42B
| $138M | 0.02% |
5,064,744
+893,573
| +21% | +$18.6M |
|
442
Newmont
NEM
$120B
| $137M | 0.02% |
2,897,602
+1,719,071
| +146% | +$76.7M |
|
443
Grupo Aeroportuario del Pacifico
PAC
$12.4B
| $137M | 0.02% |
950,722
-94,135
| -9% | -$14.4M |
|
444
Novanta
NOVT
$6.33B
| $134M | 0.02% |
985,144
+517,824
| +111% | +$72.5M |
|
445
CenterPoint Energy
CNP
$26.7B
| $133M | 0.02% |
4,450,521
-95,149
| -2% | -$2.77M |
|
446
Entergy
ETR
$49.9B
| $133M | 0.02% |
2,363,548
-594,296
| -20% | -$32.6M |
|
447
Ventas
VTR
$46.3B
| $132M | 0.02% |
2,921,765
+231,037
| +9% | +$9.74M |
|
448
Tyler Technologies
TYL
$13.5B
| $132M | 0.02% |
408,164
+15,413
| +4% | +$5.03M |
|
|
AKRO
449
DELISTED
Akero Therapeutics
AKRO
| $132M | 0.02% |
2,401,037
+938,613
| +64% | +$40.2M |
|
450
Manhattan Associates
MANH
$11.7B
| $131M | 0.02% |
1,076,590
-34,908
| -3% | -$4.29M |
|
Similar funds
T. Rowe Price Associates's Q4 2022 Portfolio in Review
As of Q4 2022, T. Rowe Price Associates held 3,066 positions worth $622B, up 1.8% from $610B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
T. Rowe Price Associates's Q4 2022 filing shows 113 new, 1,569 increased, 1,081 reduced and 107 closed positions. Its largest new stake was GE HealthCare: 6,360,001 shares worth $371M. The largest sale was Amazon, an estimated $6.33B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 26% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q4 2022 buy was GE HealthCare: 6,360,001 shares worth $371M.
- T. Rowe Price Associates added most to JPMorgan Chase in Q4 2022, an estimated $1.6B increase.
- T. Rowe Price Associates's biggest Q4 2022 reduction was Amazon, cutting an estimated $6.33B.
- T. Rowe Price Associates fully exited Terminix Global Holdings, Inc. in Q4 2022, selling an estimated $3.44B.
- T. Rowe Price Associates's ten largest holdings make up 27% of its $622B portfolio in Q4 2022.
- T. Rowe Price Associates opened 113 new positions and closed 107 in Q4 2022.
- T. Rowe Price Associates's portfolio value rose 1.8% quarter-over-quarter to $622B.
Based on T. Rowe Price Associates's 13F filing for Q4 2022, filed 14 Feb 2023.